US2023138411A1PendingUtilityA1

Pyrimidine compound

Assignee: OTSUKA PHARMA CO LTDPriority: May 31, 2017Filed: Dec 30, 2022Published: May 4, 2023
Est. expiryMay 31, 2037(~10.8 yrs left)· nominal 20-yr term from priority
C07D 239/22C07F 7/0812C07D 403/04A61K 31/513C07D 239/54A61P 25/08C07D 401/14
77
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides a novel pyrimidine compound represented by Formula [I] and a salt thereof:[in the formula, the symbols are as defined in the specification], which is useful for treating, preventing and/or diagnosing seizure and the like in disease involving epileptic seizure or convulsive seizure (including multiple drug resistant seizure, refractory seizure, acute symptomatic seizure, febrile seizure and status epilepticus), as well as a medical use therefor.

Claims

exact text as granted — not AI-modified
1 . A method for diagnosing seizure in diseases involving epileptic seizure or convulsive seizure (including multiple drug resistant seizure, refractory seizure, acute symptomatic seizure, febrile seizure and status epilepticus), which comprises administering to a human in need thereof an effective amount of a compound represented by Formula [I]: 
       
         
           
           
               
               
           
         
         wherein 
       
       ring A is phenyl, naphthyl or pyridyl;
 R 1  is lower alkyl; 
 R 2  is —O-lower alkyl; 
 R 3  is halogen, lower alkynyl, lower alkyl optionally substituted with halogen, —O-lower alkyl optionally substituted with deuterium or halogen, —S-lower alkyl optionally substituted with halogen, phenyl, pentafluorothio, —CN, —O-benzyl or —Si-mono-, di- or tri-lower alkyl wherein di or tri may be same or different alkyl; 
 L is bond, lower alkylene, —O— or —S—; 
 each of m and n is 0 or 1; 
 q is 0, 1 or 2, and when q is 2, each R 3  independently represents the same or different substituent; and 
    represents single or double bond, 
 or a salt thereof. 
 
     
     
         2 . The method according to  claim 1 , wherein
 ring A is phenyl,   L is —O—, and   n is 0.   
     
     
         3 . The method according to  claim 1 , wherein m is 0. 
     
     
         4 . The method according to  claim 1 , wherein R 3  is halogen, lower alkynyl, lower alkyl or —S-lower alkyl optionally substituted with halogen. 
     
     
         5 . The method according to  claim 1 , wherein 
       
         
           
           
               
               
           
         
         is phenyl, monohalophenyl, dihalophenyl, mono-lower alkynylphenyl or mono-lower alkylphenyl or phenyl substituted with one halogen and one lower alkyl group. 
       
     
     
         6 . A method for diagnosing seizure in diseases involving epileptic seizure or convulsive seizure (including multiple drug resistant seizure, refractory seizure, acute symptomatic seizure, febrile seizure and status epilepticus), which comprises administering to a human in need thereof an effective amount of a compound selected from the group consisting of the following compounds:

Join the waitlist — get patent alerts

Track US2023138411A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.